{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:50Z","timestamp":1793726030399,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","award":["ILT-101"],"award-info":[{"award-number":["ILT-101"]}],"id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaut.2024.103172","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:58:51Z","timestamp":1707325131000},"page":"103172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2405-9388","authenticated-orcid":false,"given":"Roberta","family":"Lorenzon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ribet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Pitoiset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Aractingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Banneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Beaugerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Berenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Champey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouilleres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Regnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rosenzwajg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-3422","authenticated-orcid":false,"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103172_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fimmu.2018.00786","article-title":"Targeting regulatory T cells to treat patients with systemic lupus erythematosus","volume":"9","author":"Mizui","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib5","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103172_bib6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103172_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103172_bib8","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.jaut.2024.103172_bib9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2018.06.006","article-title":"Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2","volume":"142","author":"Churlaud","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103172_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103172_bib12","article-title":"S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial","volume":"9","author":"Humrich","year":"2022","journal-title":"Lupus Science & Medicine"},{"key":"10.1016\/j.jaut.2024.103172_bib13","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"10.1016\/j.jaut.2024.103172_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaut.2024.103172_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Gene Immun."},{"key":"10.1016\/j.jaut.2024.103172_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib17","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103172_bib18","first-page":"1","article-title":"Low-dose IL-2 therapy in autoimmune diseases: an update review","author":"Zhang","year":"2023","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103172_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103172_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1089\/gtmb.2013.0291","article-title":"Polymorphisms in the IL2RA and IL2RB genes in inflammatory bowel disease risk","volume":"17","author":"Bouzid","year":"2013","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.jaut.2024.103172_bib21","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/ecco-jcc\/jjab103","article-title":"A Crohn's disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signalling","volume":"15","author":"Goldberg","year":"2021","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.jaut.2024.103172_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2350-10-22","article-title":"Contrasting genetic association of IL2RAwith SLE and ANCA \u2013 associated vasculitis","volume":"10","author":"Carr","year":"2009","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.jaut.2024.103172_bib23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103172_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jaut.2024.103172_bib25","unstructured":"Low-dose Interleukin-2 and Rapamycin on sj\u00f6gren\u2019s Syndrome , (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05605665?term=IL2&cond=Sj%C3%B6gren&draw=2&rank=1 (accessed March 27, 2023)."},{"key":"10.1016\/j.jaut.2024.103172_bib26","series-title":"Kernel Networks Inc., Low-Dose IL-2 Treatment on Behcet's Disease","year":"2019"},{"key":"10.1016\/j.jaut.2024.103172_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09633.x","article-title":"Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea","volume":"162","author":"Antiga","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2024.103172_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","article-title":"Regulatory T cells (CD4+ CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity","volume":"261","author":"Slobodin","year":"2010","journal-title":"Cell. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:41:21Z","timestamp":1738417281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"alternative-id":["S0896841124000064"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103172","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103172"}}